Target intelligence / Profile preview

Tectonin beta-propeller repeat-containing protein 1 (TECPR1)

Target
TECPR1
Molecular classification
Other (Autophagy tethering factor and autophagy regulator), Receptor (recognizes cytosolic sphingomyelin for selective autophagy), Beta-propeller repeat-containing protein
01

Overview

Tectonin beta-propeller repeat-containing protein 1 (TECPR1) is a **tethering factor** involved in autophagy, responsible for promoting autophagosome maturation and fusion with lysosomes[1][3][12]. This protein acts as a selective autophagy receptor that recognizes cytosolic sphingomyelin exposed on damaged endomembranes, such as those created during bacterial infection, and is required for LC3 conjugation onto these membranes[5]. TECPR1 accomplishes this by associating with ATG5-ATG12 and phosphatidylinositol-3-phosphate, functioning independently of the canonical autophagy protein ATG16L1 in this context. Mutations in TECPR1 are linked to neurodegenerative diseases, including hereditary spastic paraplegia type 49 and frontotemporal dementia/ALS 7, underscoring its importance for neuronal health and cytoplasmic homeostasis[3]. No current therapeutic modulators are reported, but its unique autophagy roles suggest future interest as a disease or infection target.

Other names
TECPR1KIAA1358DKFZP434B0335FLJ23419FLJ90593
02

Mechanism of action

None reported for known therapeutics; however, TECPR1 acts by recruiting ATG5 into an E3 ligase complex for LC3 conjugation to damaged endomembranes upon sphingomyelin exposure, independent of ATG16L1[5].

03

Biological functions

Autophagy (tethering factor, autophagosome maturation, selective autophagy against protein aggregates, damaged mitochondria, and bacteria)Phagocytosis (signalling, recognition of bacterial danger signals)Lysosomal targeting/fusionLipid and membrane recognition (specifically sphingomyelin exposure in damaged endomembranes)
04

Disease associations

Neurodegenerative disease (Hereditary spastic paraplegia 49, Frontotemporal dementia and/or amyotrophic lateral sclerosis 7)Potential role in infection (bacterial pathogen selectivity)Other (mutations associated with hereditary neurological disorders as above)
05

Safety considerations

None specifically described for direct targeting; possible challenges could include effects on fundamental autophagy mechanisms and risk of disrupting cellular homeostasis.
06

Biomarkers

None established for patient selection or efficacy monitoring; pathogenic variants may serve as biomarkers for hereditary spastic paraplegia.

Beyond the preview

Go deeper on Tectonin beta-propeller repeat-containing protein 1 (TECPR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tectonin beta-propeller repeat-containing protein 1 (TECPR1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call